Top of page
Health

World-First trial offers hope to children with Duchenne Muscular Dystrophy

MUSCULAR DYSTROPHY words written on label tag with medicine,syringe,keyboard and stethoscope with wood background

Three boys in NSW have become the youngest patients in the world to receive therapy for Duchenne Muscular Dystrophy as part of a world-first international clinical trial for children aged under four. 

Duchenne muscular dystrophy (DMD) is a rare and life-limiting genetic condition mostly affecting boys that causes rapid muscle weakness and results in almost all patients needing a wheelchair by 12 years of age.

There is no known cure.

The trial will recruit 10 boys under four years of age worldwide, with patients followed over a period of at least five years to measure the therapy’s effectiveness, including three in NSW who are being treated at The Children’s Hospital at Westmead.

The DMD clinical trial will use a novel viral vector-based gene replacement therapy to target DMD at its root cause, replacing the faulty or mutated gene with a healthy version in a single-dose infusion.

Current management of DMD involves high-dosed steroids, combined with physical therapy and allied health support but while it can lead to some improvement, it is also associated with difficult side effects and is not a long-term treatment.

Gene replacement therapy has already shown success in treating other genetic conditions, including spinal muscular atrophy (SMA), a condition causing rapidly progressive muscle weakness and early death in children.

NSW Premier Chris Minns said: “This new gene therapy represents a beacon of hope for these three young boys and their families.”

“I’m very proud that NSW is a part of the world trial for this debilitating disease.”

“The Sydney Children’s Hospitals Network has the expertise and capability to deliver world-leading paediatric clinical trials like this, which can lead to major clinical improvements for these children.”

 

You might also like

Person performing a exercise. Person performing a exercise.

New exercise method offers relief for people with rheumatoid arthritis

It’s a debilitating disease that affects more than 500,000 Australians,…

The Club’s Head of Charities (Positive Ageing & Elderly Care; and Healthy Community) Imelda Chan (3rd left) poses for a photo with a beneficiary of JCECC: Unison (3rd right) and other guests. The Club’s Head of Charities (Positive Ageing & Elderly Care; and Healthy Community) Imelda Chan (3rd left) poses for a photo with a beneficiary of JCECC: Unison (3rd right) and other guests.

HK launches project to improve end-of-life care for persons with disabilities

Hong Kong has launched a new initiative to improve end-of-life…

Audience member asking a question during the launch of the WHO Disability Health Equity Initiative Audience member asking a question during the launch of the WHO Disability Health Equity Initiative

WHO launches Disability Health Equity Initiative

WHO has launched the WHO Disability Health Equity Initiative, a global…

Sign Language Interpreter for DeafBlind Sign Language Interpreter for DeafBlind

Deafblind organisations call for care standards as safety concerns mount

This Deafblind Awareness week (June 23 to June 29), leading Deafblind…